Company Profile¨Š映光電簡報EN1061102.pdf · Company Profile Company Milestones Organization...

OK Biotech－ Your Best Manufacturing Partner

for Blood Glucose Meters www.okbiotech.com

Company Profile Presenter : Jerry Fang (Spokesmen/Special Assistant to President) 2nd November 2017



Energetic Dynamic Excellence Innovative High Technology, World class

product quality

1



Company Profile Company Milestones Organization Structure Board of Directors

Market Status Main Players Analysis

Complete Product Portfolio Product features Sales development Market presence Financial information (past 3 years)

Research & Development and patents Standards & product certification Technology advantages

Management philosophy Corporate governance Corporate Social Responsibility

Development directions Visions

2



Capital NTD 655 million

Employees 92 in total

Address No. 91, Sec. 2, Gongdao 5th Rd., Hsinchu

Chairman/CEO James Lai

Industry Trade Biomedical Industry

Main Products Blood Glucose Meter, Blood Glucose Test strips and

other medical monitoring devices

Main Territories USA, Middle East, Europe, India, China, across five

continents, existence in 60+ countries

Rank within same trade 4th in Taiwan, based on sales revenue

Annual Capacity 720 million of blood glucose test strips in Y2016

Up to 1.2 billion upon establishment of second

manufacturing facility by end of Y2017

Strips Capacity 17 lines + 8 lines (2nd manufacturing facility)

Brand Own Brand Okmeter & Co-Brand Prodigy

3



• Company founded

• R&D and pilot run in meters and test strips

• Acquire Taiwan GMP & ISO 13485

• Product acquire FDA 510(k), CE (CE 0123) & CFDA

• Global first 6 seconds glucose reaction time device

• Aug – First batch of products delivered to US

• Completed development of Global first voice glucose meter

• Become Taiwan 4th largest manufacturer in BGMS

• Dec – Taiwan listed company at emerging stock market

• Mar - Acquire 45% stake in US Prodigy

• May – Establishment of Hsinchu Headquarters

• Oct – Pass FDA factory inspection

• Dec – Receive Forbes Asia’s Annual Top 200 Small & Midsize companies award

• Mar – Establish Miaoli OKB Medical Supplies

• May – Lawsuit settlement with Taidoc

• May – Invest set-up OK Health Corporation

• Feb – Completed CSR and certified by SGS

•Promote overseas cooperation in manufacturing establishment

•Aug – Record high in sales revenue

4



Stockholders

Meetings

Board of Directors

Chairman

CEO

QA Dept

Director

Daniel Wang

Production Dept

Director Sam Wu

Administrative

Dept

Sales Dept

VP Joanna Wang

R&D Dept

Director Anson Li

Audit Office

Audit Committee Remuneration

committee

5

Average Length of Service：Abt 9 years



Title Name Qualifications/Experience

Chairman/CEO James Lai National Chiao Tung University-Department of Industrial

Management/HMD Biomedical Production Manager

Director Chang Te-Chuan National Taipei University of Technology-Department of Electro-

Optical Engineering/US Johnson & Johnson Manager

Director Chang Te-Cheng Lunghwa University of Science and Technology-Department of

Electrical Engineering/We Joing Enterprise Factory Manager

Director Wu I-Ming Flihi Technology Co., Ltd - President

Independent

Director Hsieh Yun-Kuei

Oriental Institute of Technology-Department of Electronics

Engineering/Pintek Information Co., Ltd Manager

Independent

Director Chiang Chao-Feng

Feng Chia University – Department of Risk Management &

Insurance/Tamkang University Risk Management & Insurance

Lecturer

Independent

Director Chen Yuan-Cheng

Soochow University – Department of Accounting/Mitac

International Corporation Finance Manager

6



1 in 11 adults have diabetes

※Sources from IDF Diabetes Atlas 2015, 7th Edition

415 million

642 million

7



One adult in eight has diabetes in the North America and Caribbean region


8



12% of global health expenditure is spent on diabetes


12%

9



0

50

100

150

Billion $

88 100

114

BGM Global market scale

Y2013 Y2016 Y2019

※Source： 2015 TriMark Publications, LLC

Annual growth rate in global BGM systems is 4%-5%

US, Europe, Japan

80%

Roche & 3 other major

players

78% China, India,

SEA

High Growth

Rate

10



Roche

25%

Johnson & Johnson

23%

Bayer

16%

Abbott

14% Others

22%

Global BGMS products’ market share and status

※Source: 1. Market Share：Year 2017 Medical Device Yearbook Published by ITRIEK 2. Panasonic Healthcare Holdings Completes Acquisition of Leading Diabetes Care Business from Bayer AG:

http://www.businesswire.com/news/home/20160104006641/en/Panasonic-Healthcare-Holdings-Completes-Acquisition-Leading-Diabetes

3. Johnson & Johnson Offers Weak Outlook, May Look To Sell Diabetes Units: http://etfdailynews.com/2017/01/24/johnson-johnson-offers-weak-outlook-may-look-to-sell-diabetes-units

4. Roche considering sale of Diabetes Care unit ($5bn): http://www.goinpharma.com/en/roche-considering-sale-of-diabetes-care-unit-5bn

11

5th Jan 2016: Panasonic Healthcare announced completion of acquisition of Bayer AG’s Diabetes Care business 24th Jan 2017: Johnson & Johnson offered a tepid outlook, and said it would look to sell its diabetes treatment units. 31st Jan 2017: Roche Diagnostics reportedly considering selling – partially or totally – its Diabetes Care business unit 4 major players gradually release some market share Second-tier manufacturers accelerate to rise



2006~2008 2009~2010 2011~2013 2014 2015 2016~

Total energy concept in R&D capability, providing products with minimum blood sampling volume (0.3μL) and shortest reaction time (5seconds )

PalmDoc

DiagnoCheck

3 in 1

DocSky

Pro-Trak

Easy Test

Concept

iConnect

Connect

Astro

Trio

Core Match II

AutoCode Eject Nebulizer II Hitech II

Eject

Direct

Lumina

Link

Optima

Premia

Hitech

Nebulizer

Match

Cameo

OKmeter 1st generation

Prodigy AutoCode

Prodigy Pocket

Prodigy Voice

Non-Invasive Combo-Meter

12



High Stability (CV<4%) , quality in pace with international manufacturers Compliance with EN ISO15197:2015 international testing standards

13

IDT Germany

TÜ V Netherlands

PSHI Germany

CV

<4%

EKF Germany

PSHI Germany laboratory clinical tests (2017.08)

PFÜTZNER Science & Health Institute GmbH ◎ MARD <7.9% (state-of-the-art quality level)

EKF Germany clinical tests (2009.08.27)

◎ Accuracy 96.3%

◎ Repeatability CV at 2.5%

IDT Germany (Institute for Diabetes-Technology GmbH)

Clinical tests (2011.04.19)

◎ Accuracy 98.5-99.5%

TÜV Rheinland entrust Isala Netherlands hospital clinical tests (2016.03.10)

◎ Accuracy>96%



CV

<4%

Providing various product models and specifications to fulfill different customers’ requirements.

14

Sampling 0.3㎕

GDH

Technology in minimum blood sampling volume and shortest reaction time

PSHI Germany

EKF Germany

IDT Germany

TÜ V Netherlands

Reaction time 5s



US, India, China, UK,

Iran, Russia, Egypt

Sales Strategy Measures

according to local conditions

Taiwan Turkey

Bangladesh Cyprus

North Africa, Middle East,

South Europe, South Asia, West Asia

15



Sales across five continents, existence in 60+ countries

Feb 2014 Established Guangzhou

Sunyang Electronic Technology Co., Ltd

(100% own)

Mar 2015 onwards Establish OK Medical

Supplies

Jan 2016 Established OK Biotech Co..

Ltd in Tokyo (100% own)

Mar 2013 Acquired 45%

stake in Prodigy Diabetes Care LLC

16



Units：NT Thousands ; NT$

Y2014 Y2015 Y2016 First Half

of Y2017

3rd Qtr

of Y2017

Revenue 633,765 856,551 1,040,462 626,996 343,581

Gross Profit 178,001 281,409 216,506 132,149

Operating Income 38,456 113,249 110,598 69,229

EPS 1.17 1.77 1.36 0.95

Stock Dividend 2 0 0

Cash Dividend 0.2 1.55 1.55

0

200,000

400,000

600,000

800,000

1,000,000

1,200,000

17

N/A

N/A

N/A

N/A

N/A

N/A

N/A

(*1)

(*2)

*1：Included NT$1 surplus, NT$1 Capital Reserve

*2： Included NT$1.13 surplus, NT$0.42 Capital Reserve



Over 30 models of BGMS, nebulizers & various new medical devices

Test strips patents

Blood sampling detection

Test strips vials

patents

Vials moisture proof function

Performance

M.S B.S

Strong R&D Lineup

Nebulizer’s patent

Liquid agent leak proof structure

18

Blood glucose meters patents

Meter with attachable vial

PH.D.



ISO13485

CMDCAS

GMP

FDA

CE

CFDA

Free Sales

MDSS

EKF

IDT

TÜV

19



Electro-chemical

GOD

GDH Carbon

electrode

Gold electrode

Distant Healthcare

Bluetooth Transmission

Mobile Transmission

20



Committed to

taking care of

employees and

shareholders with

sustainable

management

Mutual benefits among

customers, vendors and

company

Goal in becoming

excellent

enterprise and

exercising CSR

21



22

1. OK Biotech formed 3 independent directors within Board of Directors from Year 2009.

2. Ok Biotech set up audit and remuneration committee in compliance to regulations and both committee members formed by independent directors.

3. The candidates for election of all directors are nominated based on revision of articles in the shareholders’ meeting in Year 2017

4. Directors & independent directors are invited to attend the shareholders’ meeting held in Year 2017 (2 independent directors and 3 directors attended)

5. Electronic nomination will be adopted for shareholders’ meetings with effect from Year 2018.



23

Indicators Implemented On-

going Sub-total Total (%) Total

Maintain shareholder equity

8 2 10 76.92% 13

Shareholders’ equality 9 2 11 73.33% 15

Strengthen structure & operation of board of directors

27 0 27 77.14% 35

Enhancing information transparency

14 1 15 71.43% 21

Implement CSR 9 2 11 73.33% 15

Others 4 0 4 100.00% 4

Total 71 7 78 75.73% 103



• Comprehensive company governance

• Create shareholders’ value • Sustainable development

strategy • Financial information &

Operational performance/Prospects

• Implement environment protection

• Promote sustainable management

• Completed Greenhouse Gas Emissions verification

• Completed Carbon • Footprint verification

• Engage in social care • Engage in social health

examination • Engage & sponsor in Charitable

activities • Annual National OK cup table

tennis competition

OKB has fully implemented CSR in contribution to society excellence and sustainability in management!

24

OK Biotech in reference book for sustainability



• Fully automated production equipment

• Establishment of second production facility

• Provide support in overseas manufacturing transfer

• Non-invasive BGMS • Long-range transmission • Multi functional detection • 3-in-1 combo monitoring

device • Hearing aids,

electrotherapy instrument, movement aids

• Acquiring financing channels after IPO

• Financial information disclosure promptly

• Sales across 100+ countries

• Product portfolio enhance and integration with different industry

• Production technology transfer based on requirements

• Surpass competitors,

ascending towards

international leading brand

Sales R&D

Finance Production

25



Commitment in lifelong care towards diabetes patients.

Becoming the leading brand with excellent quality in Taiwan’s home medical

products.

26



Measure Blood Glucose frequently ‧ OKmeter

27

Company Profile¨Š映光電簡報EN1061102.pdf · Company Profile Company Milestones Organization...

Documents

Transcript of Company Profile¨Š映光電簡報EN1061102.pdf · Company Profile Company Milestones Organization...